Healthcare
We speak the same language as healthcare professionals and executives. With a specialized team, we ensure a targeted approach to planning, engagement, and negotiation.
We speak the same language as healthcare professionals and executives. With a specialized team, we ensure a targeted approach to planning, engagement, and negotiation.
Deals completed in this sector
Countries where deals took place
Specialists dedicated to this sector
trade shows, exhibitions, and conferences mapped globally
billion USD transacted with international investment funds
Context
Vydence Medical is a leading company in the medical aesthetics market, with more than 30 years of experience and recognized for its comprehensive portfolio of high-tech equipment and strong capacity for innovation. Its factory, located in São Carlos (SP), specializes in producing laser equipment focused on dermatology, vascular surgery, and plastic surgery. With a consolidated international presence, the company exports to more than 30 countries, including the United States and Europe.
Grupo MedSystems, which counts XP as an investment partner, is a leader in the global medical aesthetics market, with a strong focus on innovation and international expansion.
Strategic Rationale
The acquisition of Vydence Medical by Grupo MedSystems strengthens MedSystems’ leadership in the global medical aesthetics market and significantly expands its innovation potential. By incorporating Vydence’s expertise, technology portfolio, and international presence, MedSystems enhances its ability to serve clients across different regions of the world and consolidates its position as one of the leading global players in high-performance medical aesthetics solutions.
The transaction also reinforces MedSystems’ strategy of sustainable growth and internationalization, while opening new opportunities for Vydence to continue developing cutting-edge technology with global reach.
Context
CT Group, a leading distributor of surgical and medical devices in Brazil, has been invested in by Bunzl plc, the specialist international distribution and services Group.
Founded in 1997, CT Group is a national leader in the surgical and medical device market in Brazil, with a focus on neurosurgery and spinal area.
CT Group connects exclusive and premium manufacturers with a wide range of hospitals and insurance companies throughout the country. The company has built a strong reputation for delivering innovative and high-quality medical devices, ensuring reliable supply and specialized logistics to meet the industry's demands.
Bunzl plc is the global leader in value-added distribution and continues to expand its operations in over 30 countries across the Americas, Europe, Asia Pacific, and the UK & Ireland. With a workforce exceeding 20,000 employees worldwide, the company is aleading player in the distribution of healthcare, hygiene, safety, grocery, and food service products.
Strategic Rationale
The investment in CT Group, which was advised by igc partners, will boost Bunzl’s growth in Brazil in the medical devices segment, in addition to expanding its geographic presence in the health market.
Context
Grupo JL Health is a holding company operating in the dermatology, plastic surgery, and ophthalmology segments, with offices in Brazil, Colombia, and Argentina. Among its companies is MedSystems, the largest distributor and importer of medical equipment for dermatological treatment, health, and wellness in Latin America, with over 20 years of experience in the sector.
The group also includes MedBanking, a platform that provides financial solutions for healthcare companies and professionals, and Med Academy, focused on training and educational programs for the dermatology and plastic surgery markets. With an end-to-end provider model, JL Health covers the entire value chain — from curation and regulatory processes to technical support — and reported R$ 520 million in revenue in 2022, with expectations to reach R$ 700 million in 2023.
XP Private Equity, the private equity investment arm of XP, acquired a minority stake in the company in one of the largest transactions ever carried out in Brazil by a private equity fund in the dermatological technology sector.
Strategic Rationale
The investment by XP Private Equity will enable Grupo JL Health to accelerate both its organic and inorganic growth plans. Key priorities include strengthening areas where it already operates more discreetly and expanding into new high-potential segments such as gynecology, ophthalmology, and orthopedics.
The partnership also enhances the holding company’s financial and strategic capacity to expand its portfolio and consolidate its leadership position as the leading integrated medical technology platform specializing in aesthetics, health, and wellness in Latin America.
Context
Laboratório Homeopático Almeida Prado is a leading Brazilian homeopathic pharmaceutical company, founded in 1959 in São Paulo by homeopath and researcher Estevam José de Almeida Prado and pharmacist Rubens Gimenes. A pioneer in industrialized homeopathy in Brazil, the company became known for launching a line of homeopathic medicines modeled after European and North American standards. Today, Almeida Prado is a benchmark in the homeopathic pharmaceutical industry, recognized for producing effective and safe homeopathic medicines.
Headquartered in Uruguay, Megalabs is one of the largest pharmaceutical companies in Latin America, with operations in 18 countries, over 8,000 employees, and a portfolio of more than 1,800 products. Since 2016, Megalabs has been strengthening its presence in Brazil through product launches, acquisitions, licenses, and partnerships, building a strong position in the country’s pharmaceutical market.
Strategic Rationale
The acquisition of Almeida Prado’s recognized and traditional product, Complexo 46 (AP46), strengthens Megalabs’ market position in the gastroenterology segment and expands its over-the-counter (OTC) portfolio in Brazil. This transaction allows Megalabs to leverage AP46’s brand equity and long-standing consumer trust, boosting sales and reinforcing its growth strategy in the Brazilian OTC and gastroenterology markets.
Context
Blue Health is a leading provider of medical equipment solutions, operating in the rental, maintenance, and sale of imaging equipment, as well as reagents for in vitro diagnostics. With more than 20 years of experience, the company has established itself as one of the largest healthcare solution ecosystems in Brazil, with a strong presence in cutting-edge technology and personalized services. In June 2022, it received a R$ 200 million investment from Kinea Private Equity, the private equity arm of the Itaú group, in exchange for a minority stake.
Strategic Rationale
The investment from Kinea will enable Blue Health to accelerate its organic and inorganic expansion plan in a highly fragmented market with significant growth potential. The transaction enhances the company’s ability to broaden its operations, consolidate its presence in new healthcare niches, and strengthen its infrastructure, further establishing itself as a benchmark in imaging diagnostics and medical services in Brazil.
Context
Founded in 1996, Prontmed specializes in providing structured clinical data through electronic medical records to support population health management. Currently used by around 7,000 physicians across Brazil, the platform integrates clinical information and generates intelligence tailored to the needs of different medical specialties.
The Fleury and Sabin Groups, national references in diagnostic medicine, acquired a combined 30% minority stake in Prontmed.
Strategic Rationale
The investment will enable Prontmed to expand its user base, accelerate the development of new features, and reinforce its position as a reference in structured clinical data in Brazil. For Fleury and Sabin, the transaction enhances their ability to offer integrated, evidence-based solutions, strengthening healthcare efficiency and the integration of medical data on a national scale.
Context
BSN Medical, part of the Essity Group, is a global developer, manufacturer, and distributor of medical products in the areas of wound care, compression therapy, and orthopedics. Neve Indústria e Comércio de Produtos Cirúrgicos, founded in 1986 and headquartered in Bragança Paulista (SP), manufactures surgical, orthopedic, protective, and hospital apparel product lines. It serves over 1,500 hospitals and employs approximately 400 people.
Strategic Rationale
In August 2019, BSN Medical sold all assets of its Neve division to a group of Brazilian investors. The transaction allowed BSN to focus on its core global strategy, while Neve gained greater operational autonomy under local management, maintaining domestic production and direct service to the hospital market.
Context
Femme Laboratório da Mulher is a diagnostic center exclusively focused on women's health, currently operating five units in São Paulo. Founded by doctors Professor Dr. Rogério Ciarcia Ramires and Professor Dr. Décio Roveda Júnior, Femme offers services including diagnostic gynecology, ultrasound, fetal medicine, breast imaging, genetic testing, pathology, and blood tests.
L Catterton is the world’s largest consumer-focused private equity firm, founded as a joint venture between Catterton, LVMH, and Groupe Arnault. It manages over US $15 billion across multiple funds focused on the consumer and health sectors.
Strategic Rationale
L Catterton’s investment is intended to fuel Femme’s national expansion by scaling its clinic network, adding new services, and enhancing marketing efforts. The strategic partnership leverages L Catterton’s deep expertise in growing consumer-health platforms across Latin America, positioning Femme to elevate its brand and accelerate growth.
Context
Osler Laboratory, a Brazilian manufacturer of insect repellents, is best known for its Exposis® brand, a premium line of picaridin-based products widely sold in pharmacies across Brazil. The company built a strong reputation in the Brazilian market for effective, high-quality repellents targeted at consumers seeking advanced protection.
SC Johnson, headquartered in Racine, Wisconsin (USA), is a global leader in household and personal care products. Founded in 1886, SC Johnson owns iconic brands like OFF!®, Raid®, Glade®, Windex®, and Pledge®, and operates in over 70 countries.
Strategic Rationale
The acquisition of Osler Laboratory enables SC Johnson to strengthen its insect-repellent portfolio in Brazil, adding a premium, locally recognized brand to complement its existing pest-control products. The transaction expands SC Johnson’s footprint in Brazil and enhances its ability to meet consumer needs in the insect protection segment.
Context
LM Farma Indústria e Comércio Ltda., founded in 1988 and based in São José dos Campos (SP), is a Brazilian manufacturer of wound care products under the Curatec brand. Before 2011, it had built a strong presence in hospital markets with R&D-driven antiseptic dressings.
Laboratoires Urgo, part of the French Urgo Group founded in 1880, specializes in wound care and advanced healing solutions.
Strategic Rationale
The acquisition provided Urgo with local manufacturing, ANVISA certification, and an established distribution network, enabling quicker market entry and regulatory compliance in Brazil. LM Farma became Urgo’s regional platform for introducing its global wound-care portfolio, accelerating R&D investments and product expansion in Latin America.
Context
Farmasa (Laboratório Americano de Farmacoterapia S.A.) is a Brazilian pharmaceutical company specializing in high-growth prescription and direct-to-consumer medications. In November 2007, GP Investments, a major Brazilian private equity firm, acquired a significant minority stake in Farmasa through an investment and association agreement, which also included a subsequent merger with Hypermarcas, a leading Brazilian consumer health company.
Strategic Rationale
GP Investments’ stake enabled Farmasa to leverage synergies from the merger with Hypermarcas—strengthening its distribution reach, product portfolio, and operational scale. The combination created a more robust platform in Brazil’s pharmaceutical and consumer health market, positioning the merged entity for sustained growth.
Try adjusting your search filters or visit the full Transactions page for more results
A strong presence of strategic and financial buyers from North and South America, including private equity funds, family offices, and corporate acquirers across diverse industries.
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
We’ve executed numerous transactions across the region, ranging from middle-market deals to cross-border acquisitions involving leading players in key sectors.
Context
Femme Laboratório da Mulher is a diagnostic center exclusively focused on women's health, currently operating five units in São Paulo. Founded by doctors Professor Dr. Rogério Ciarcia Ramires and Professor Dr. Décio Roveda Júnior, Femme offers services including diagnostic gynecology, ultrasound, fetal medicine, breast imaging, genetic testing, pathology, and blood tests.
L Catterton is the world’s largest consumer-focused private equity firm, founded as a joint venture between Catterton, LVMH, and Groupe Arnault. It manages over US $15 billion across multiple funds focused on the consumer and health sectors.
Strategic Rationale
L Catterton’s investment is intended to fuel Femme’s national expansion by scaling its clinic network, adding new services, and enhancing marketing efforts. The strategic partnership leverages L Catterton’s deep expertise in growing consumer-health platforms across Latin America, positioning Femme to elevate its brand and accelerate growth.
Context
Osler Laboratory, a Brazilian manufacturer of insect repellents, is best known for its Exposis® brand, a premium line of picaridin-based products widely sold in pharmacies across Brazil. The company built a strong reputation in the Brazilian market for effective, high-quality repellents targeted at consumers seeking advanced protection.
SC Johnson, headquartered in Racine, Wisconsin (USA), is a global leader in household and personal care products. Founded in 1886, SC Johnson owns iconic brands like OFF!®, Raid®, Glade®, Windex®, and Pledge®, and operates in over 70 countries.
Strategic Rationale
The acquisition of Osler Laboratory enables SC Johnson to strengthen its insect-repellent portfolio in Brazil, adding a premium, locally recognized brand to complement its existing pest-control products. The transaction expands SC Johnson’s footprint in Brazil and enhances its ability to meet consumer needs in the insect protection segment.
Context
Farmasa (Laboratório Americano de Farmacoterapia S.A.) is a Brazilian pharmaceutical company specializing in high-growth prescription and direct-to-consumer medications. In November 2007, GP Investments, a major Brazilian private equity firm, acquired a significant minority stake in Farmasa through an investment and association agreement, which also included a subsequent merger with Hypermarcas, a leading Brazilian consumer health company.
Strategic Rationale
GP Investments’ stake enabled Farmasa to leverage synergies from the merger with Hypermarcas—strengthening its distribution reach, product portfolio, and operational scale. The combination created a more robust platform in Brazil’s pharmaceutical and consumer health market, positioning the merged entity for sustained growth.
A strong presence of strategic and financial buyers from North and South America, including private equity funds, family offices, and corporate acquirers across diverse industries.
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
We’ve executed numerous transactions across the region, ranging from middle-market deals to cross-border acquisitions involving leading players in key sectors.
Context
Founded in 1996, Prontmed specializes in providing structured clinical data through electronic medical records to support population health management. Currently used by around 7,000 physicians across Brazil, the platform integrates clinical information and generates intelligence tailored to the needs of different medical specialties.
The Fleury and Sabin Groups, national references in diagnostic medicine, acquired a combined 30% minority stake in Prontmed.
Strategic Rationale
The investment will enable Prontmed to expand its user base, accelerate the development of new features, and reinforce its position as a reference in structured clinical data in Brazil. For Fleury and Sabin, the transaction enhances their ability to offer integrated, evidence-based solutions, strengthening healthcare efficiency and the integration of medical data on a national scale.
Context
Blue Health is a leading provider of medical equipment solutions, operating in the rental, maintenance, and sale of imaging equipment, as well as reagents for in vitro diagnostics. With more than 20 years of experience, the company has established itself as one of the largest healthcare solution ecosystems in Brazil, with a strong presence in cutting-edge technology and personalized services. In June 2022, it received a R$ 200 million investment from Kinea Private Equity, the private equity arm of the Itaú group, in exchange for a minority stake.
Strategic Rationale
The investment from Kinea will enable Blue Health to accelerate its organic and inorganic expansion plan in a highly fragmented market with significant growth potential. The transaction enhances the company’s ability to broaden its operations, consolidate its presence in new healthcare niches, and strengthen its infrastructure, further establishing itself as a benchmark in imaging diagnostics and medical services in Brazil.
Context
Grupo JL Health is a holding company operating in the dermatology, plastic surgery, and ophthalmology segments, with offices in Brazil, Colombia, and Argentina. Among its companies is MedSystems, the largest distributor and importer of medical equipment for dermatological treatment, health, and wellness in Latin America, with over 20 years of experience in the sector.
The group also includes MedBanking, a platform that provides financial solutions for healthcare companies and professionals, and Med Academy, focused on training and educational programs for the dermatology and plastic surgery markets. With an end-to-end provider model, JL Health covers the entire value chain — from curation and regulatory processes to technical support — and reported R$ 520 million in revenue in 2022, with expectations to reach R$ 700 million in 2023.
XP Private Equity, the private equity investment arm of XP, acquired a minority stake in the company in one of the largest transactions ever carried out in Brazil by a private equity fund in the dermatological technology sector.
Strategic Rationale
The investment by XP Private Equity will enable Grupo JL Health to accelerate both its organic and inorganic growth plans. Key priorities include strengthening areas where it already operates more discreetly and expanding into new high-potential segments such as gynecology, ophthalmology, and orthopedics.
The partnership also enhances the holding company’s financial and strategic capacity to expand its portfolio and consolidate its leadership position as the leading integrated medical technology platform specializing in aesthetics, health, and wellness in Latin America.
Context
Vydence Medical is a leading company in the medical aesthetics market, with more than 30 years of experience and recognized for its comprehensive portfolio of high-tech equipment and strong capacity for innovation. Its factory, located in São Carlos (SP), specializes in producing laser equipment focused on dermatology, vascular surgery, and plastic surgery. With a consolidated international presence, the company exports to more than 30 countries, including the United States and Europe.
Grupo MedSystems, which counts XP as an investment partner, is a leader in the global medical aesthetics market, with a strong focus on innovation and international expansion.
Strategic Rationale
The acquisition of Vydence Medical by Grupo MedSystems strengthens MedSystems’ leadership in the global medical aesthetics market and significantly expands its innovation potential. By incorporating Vydence’s expertise, technology portfolio, and international presence, MedSystems enhances its ability to serve clients across different regions of the world and consolidates its position as one of the leading global players in high-performance medical aesthetics solutions.
The transaction also reinforces MedSystems’ strategy of sustainable growth and internationalization, while opening new opportunities for Vydence to continue developing cutting-edge technology with global reach.
Context
Laboratório Homeopático Almeida Prado is a leading Brazilian homeopathic pharmaceutical company, founded in 1959 in São Paulo by homeopath and researcher Estevam José de Almeida Prado and pharmacist Rubens Gimenes. A pioneer in industrialized homeopathy in Brazil, the company became known for launching a line of homeopathic medicines modeled after European and North American standards. Today, Almeida Prado is a benchmark in the homeopathic pharmaceutical industry, recognized for producing effective and safe homeopathic medicines.
Headquartered in Uruguay, Megalabs is one of the largest pharmaceutical companies in Latin America, with operations in 18 countries, over 8,000 employees, and a portfolio of more than 1,800 products. Since 2016, Megalabs has been strengthening its presence in Brazil through product launches, acquisitions, licenses, and partnerships, building a strong position in the country’s pharmaceutical market.
Strategic Rationale
The acquisition of Almeida Prado’s recognized and traditional product, Complexo 46 (AP46), strengthens Megalabs’ market position in the gastroenterology segment and expands its over-the-counter (OTC) portfolio in Brazil. This transaction allows Megalabs to leverage AP46’s brand equity and long-standing consumer trust, boosting sales and reinforcing its growth strategy in the Brazilian OTC and gastroenterology markets.
A strong presence of strategic and financial buyers from North and South America, including private equity funds, family offices, and corporate acquirers across diverse industries.
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
We’ve executed numerous transactions across the region, ranging from middle-market deals to cross-border acquisitions involving leading players in key sectors.
Context
CT Group, a leading distributor of surgical and medical devices in Brazil, has been invested in by Bunzl plc, the specialist international distribution and services Group.
Founded in 1997, CT Group is a national leader in the surgical and medical device market in Brazil, with a focus on neurosurgery and spinal area.
CT Group connects exclusive and premium manufacturers with a wide range of hospitals and insurance companies throughout the country. The company has built a strong reputation for delivering innovative and high-quality medical devices, ensuring reliable supply and specialized logistics to meet the industry's demands.
Bunzl plc is the global leader in value-added distribution and continues to expand its operations in over 30 countries across the Americas, Europe, Asia Pacific, and the UK & Ireland. With a workforce exceeding 20,000 employees worldwide, the company is aleading player in the distribution of healthcare, hygiene, safety, grocery, and food service products.
Strategic Rationale
The investment in CT Group, which was advised by igc partners, will boost Bunzl’s growth in Brazil in the medical devices segment, in addition to expanding its geographic presence in the health market.
Context
LM Farma Indústria e Comércio Ltda., founded in 1988 and based in São José dos Campos (SP), is a Brazilian manufacturer of wound care products under the Curatec brand. Before 2011, it had built a strong presence in hospital markets with R&D-driven antiseptic dressings.
Laboratoires Urgo, part of the French Urgo Group founded in 1880, specializes in wound care and advanced healing solutions.
Strategic Rationale
The acquisition provided Urgo with local manufacturing, ANVISA certification, and an established distribution network, enabling quicker market entry and regulatory compliance in Brazil. LM Farma became Urgo’s regional platform for introducing its global wound-care portfolio, accelerating R&D investments and product expansion in Latin America.
Context
BSN Medical, part of the Essity Group, is a global developer, manufacturer, and distributor of medical products in the areas of wound care, compression therapy, and orthopedics. Neve Indústria e Comércio de Produtos Cirúrgicos, founded in 1986 and headquartered in Bragança Paulista (SP), manufactures surgical, orthopedic, protective, and hospital apparel product lines. It serves over 1,500 hospitals and employs approximately 400 people.
Strategic Rationale
In August 2019, BSN Medical sold all assets of its Neve division to a group of Brazilian investors. The transaction allowed BSN to focus on its core global strategy, while Neve gained greater operational autonomy under local management, maintaining domestic production and direct service to the hospital market.
A strong presence of strategic and financial buyers from North and South America, including private equity funds, family offices, and corporate acquirers across diverse industries.
.avif)
.avif)
We’ve executed numerous transactions across the region, ranging from middle-market deals to cross-border acquisitions involving leading players in key sectors.
igc is a leader in healthcare transactions, with a strong focus on the products and services segments. We understand the dynamics of each market and, through the sector specialization of our teams, have successfully adapted to the unique characteristics of each one.
With a broad team of professionals dedicated to specific sectors, each transaction benefits from specialized expertise and deep market insight.
We focus exclusively on sell-side deals to ensure the best outcome for our clients—free from conflicts of interest.
© 2025 IGC Partners. All rights reserved. All content, materials, and information presented on this website are intended solely for general informational purposes and do not constitute legal, financial, investment, or professional advice. IGC Partners makes no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of the information provided. Users should seek appropriate independent professional advice before acting on any information contained herein. Unauthorized use, reproduction, or distribution of any part of this website is strictly prohibited. By accessing and using this website, you agree to be bound by our Privacy Policy and Terms of Use. For further through the channels provided on our Contact page.
We use cookies to improve your experience and analyze traffic with Google Analytics.
.avif)
.avif)
